Articles tagged with Cell Therapies
A new nanomedicine, ZnDHT NM, selectively targets cancer stem-like cells (CSCs) and tumor cells, promoting CSC differentiation while inhibiting EMT. This approach also leads to the release of toxic compounds in tumor cells, inducing apoptosis/ferroptosis pathways.
Researchers have developed a new gene switch that uses nitroglycerine to trigger the production of insulin and regulate blood sugar levels in people with diabetes. This switch is made exclusively of human constituents, eliminating the risk of false triggering or immune reactions.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
Researchers created optimized DNA hydrogels with fewer nucleic acids, achieving efficient and sustained drug release. The new hydrogel units showed prolonged persistence of at least 168 hours post-administration in mice, contributing to anti-tumor effects.
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
Scientists at Duke University have discovered a master epigenetic switch that can be activated using CRISPR to compensate for missing genes in Prader-Willi syndrome. This approach could potentially treat the disease by turning on naturally suppressed genes from one parent, addressing the underlying genetic defect.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
A Virginia Tech research team has made significant progress in understanding the role of physical properties in tuning the body's immune responses. By modifying biomaterials' size, shape, and stiffness, they aim to enhance immune cell behavior and stimulate antitumor immune responses.
Researchers aim to identify key mechanisms and molecular targets to prevent tumor progression in Rhabdomyosarcoma patients. The study focuses on the TAK1 protein, which plays a significant role in regulating cell growth, and its potential inhibition as a therapeutic approach.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
A new liposarcoma treatment using CAR T cells has shown promising results in clinical trials, with a response rate of 20-40% in patients with advanced or metastatic disease. Additionally, researchers have developed more efficient drug-delivery nanoparticles that can improve cancer treatment outcomes.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
CAR-T cell therapy has been shown to transfer CAR molecules to bystander T cells through trogocytosis, allowing the therapeutic effect to spread beyond the engineered cells. The study reveals that the transmembrane domains of these molecules regulate this process, potentially leading to improved efficacy and reduced side effects.
Researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a chronic inflammatory skin condition. The treatment, baricitinib, selectively blocks specific inflammatory pathways, reducing inflammation and suppressing the overactive immune response that contributes to the disease.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough in creating allogeneic CAR T cells that can persist in fighting cancer without being rejected by patients. By modifying donor cells with the HIV protein Nef, the cells can survive and remain potent in treating various types of cancer.
Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.
Researchers at JAX have successfully alleviated symptoms of multiple sulfatase deficiency using a combination of gene therapy and bone marrow transplantation. The studies, conducted in mice, offer new hope to children with the disease and provide insights into common genetic diseases.
A review of cell death and aging in cancer research reveals the significance of cellular senescence in promoting cancer growth. The study highlights the potential of various types of programmed cell death, such as necroptosis and pyroptosis, as therapeutic targets against senescent cells.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
The study establishes a consensus nomenclature and characterization framework to advance mitochondria transfer and transplantation biology. It defines types of mitochondrial transfers and reviews methods to define and enforce these processes.
New research reveals that lipid-associated macrophages (LAMs) are crucial for liver repair, while Kupffer cells also adapt to take on a LAM-like phenotype. The Trem2 gene is essential for clearance of dying liver cells and promoting tissue repair.
Researchers have identified a key protein called Apex1 as a potential therapeutic target for stopping the immune system from attacking itself. By inhibiting this protein, harmful T cells that cause autoimmune diseases and allergies can be eliminated.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
A new study published in Oncotarget discovered an anti-correlation between PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells. This finding suggests the potential for combination therapy to enhance cancer treatment by targeting both markers simultaneously, which could lead to more significant and long-lasting benefits.
Researchers found that a lower CD4+/CD8+ T cell ratio after 12-24 weeks significantly predicted HBsAg clearance in IHCs treated with peginterferon alpha. Higher baseline percentages of CD3+CD8+ cells and lower CD4+/CD8+ ratios were also associated with improved outcomes.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
Researchers at Johns Hopkins Medicine identified a new epigenetic approach to target colorectal cancer, using a mouse protein that disrupts cancer-causing chemical changes in genes. The study found that the protein, STELLA, can be used to develop a drug strategy to treat solid tumors.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
Lehigh University bioengineering researcher Tomas Gonzalez-Fernandez is exploring how combining CRISPR with biomaterials can improve gene editing's safety and efficacy for therapeutic use. His NSF CAREER award-funded research aims to develop more targeted and controlled therapies for genetic diseases.
A study by National Institute of Standards and Technology scientists has highlighted the need for standardized measurement methods in gene therapy. The researchers evaluated four techniques used to measure modified viruses deployed in some gene therapy research and treatments, finding that one technique had poor accuracy and precision.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
A new study published in the European Respiratory Journal found that extracorporeal photopheresis significantly reduces acute rejection episodes and chronic rejection risk in lung transplant patients. The treatment involves exposure to UV light, leading to apoptosis of immune cells and minimizing side effects.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
Researchers explore the role of efferocytosis in reducing inflammation and containing injury spread after an ischemic stroke. Efferocytosis may offer a promising therapeutic strategy to promote neural regeneration and minimize brain damage.
Researchers link neuropilin2 gene to autism and seizure development, highlighting its role in regulating neural circuits. The study suggests targeting specific phases of neuronal development could lead to therapeutic interventions for individuals with autism.
Researchers developed a gene therapy approach to treat chronic hypereosinophilia by delivering an anti-human eosinophil antibody via AAV-based gene therapy. The therapy successfully suppressed blood eosinophil levels in mice, showing promise as a potential treatment for the condition.
Researchers at UTHealth Houston have discovered two novel genes, DYRK1A and EGFR, linked to genetic mutations causing epileptic brain lesions. This breakthrough offers a new framework for understanding epilepsy and developing targeted therapies.
Researchers will analyze tissue samples from 100 patients over three years to understand why some respond better than others to biologic and targeted therapies. The study aims to improve matching of treatments to individual patients, reducing the guesswork and cost associated with ineffective treatment.
Researchers have made a major breakthrough in synthetic biology by developing a new construction kit for building custom sense-and-respond circuits in human cells. The new approach harnesses the power of phosphorylation to amplify weak input signals into macroscopic outputs, enabling rapid response times and sensitivity to external sig...
Researchers developed a new tool to measure biological aging in individual cell types, providing insights into diseases like Alzheimer's and liver pathologies. The study found that certain brain cells and liver cells show signs of accelerated aging, making it a better tool for detecting diseases.
Researchers developed AI-driven therapeutic platform mimicking viral structures to deliver therapeutic genes to target cells. The innovative approach achieved precise symmetrical structures and effectively delivered payloads, paving the way for breakthroughs in gene therapies and next-generation vaccines.
Researchers have found that loosening the grip of engineered chimeric antigen receptor (CAR) Tregs improves their function and effectiveness in treating autoimmune diseases. By adjusting the affinity of the CAR, the study shows that Tregs can suppress immune responses while reducing pro-inflammatory consequences.
Nearly 50 ISS National Lab-sponsored payloads splashed down safely on SpaceX’s CRS-31 mission, including research for early cancer detection and neurodegenerative conditions treatments. The investigations leveraged the space station's unique environment to improve life on Earth.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
The study, published in Aging, introduces a new therapy for osteoarthritis that uses extracellular vesicles derived from fat tissue to repair damage caused by aging cells. The treatment showed strong therapeutic effects in both cellular and mouse preclinical studies, reducing inflammation and DNA damage markers in human joint cells.
A new study found that heat therapy positively modulates multiple physiological parameters in APP/PS1 mice, with improved memory in males and worsening effects on females. This highlights the importance of personalized treatments based on sex-specific responses to therapy.
Engineered yeast cells can form cooperative groups that perform complex tasks and self-regulate in response to external signals. This approach enables precise production of therapeutic compounds, reducing waste and increasing treatment efficacy.
Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
Researchers compared urine NAA levels in patients with mild and typical Canavan disease, finding lower levels in those with the milder form. This discovery has potential for a rapid and cost-effective way to screen for CD incidence and severity.